Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Urology · Prostate Cancer

What Is the Next Step After a High PSA? Testing Path

At a Glance

A high PSA does not automatically mean prostate cancer. Doctors typically confirm the result, check for benign causes and medication effects, refine risk with PSA density or other tests, and use prostate MRI to decide whether a biopsy is needed.

Who this is for: This page explains the diagnostic pathway for someone with a newly discovered high PSA who has not yet been diagnosed with prostate cancer. If you already have a prostate cancer diagnosis and are on active surveillance or have had treatment, a rising PSA requires a different conversation with your oncology team.

A high PSA (Prostate-Specific Antigen) test does not automatically mean you have prostate cancer. PSA is a protein produced by the prostate, and it can rise for many reasons. Because PSA testing alone cannot diagnose prostate adenocarcinoma, an immediate prostate biopsy is rarely the very next step for a mildly elevated result [1][2]. Instead, doctors use a step-by-step diagnostic pathway designed to rule out non-cancerous causes, evaluate your personal risk, and avoid unnecessary procedures.

(Note: If your PSA is extremely high, or if you have urgent symptoms like an inability to urinate, severe pelvic pain, or a fever, your doctor may expedite your evaluation rather than waiting for routine repeat tests).

1. Confirming the Result and Checking for Benign Causes

Before moving forward with cancer diagnostics, your doctor will want to ensure the high PSA is an accurate reflection of your baseline risk and not caused by a temporary or benign (non-cancerous) issue.

  • Repeat the PSA Test: PSA levels can fluctuate. In fact, research shows that up to 38% of initially high PSA results normalize when retested a few weeks later [1]. While normalization does not completely rule out cancer, your doctor will likely order a second test to confirm the elevation before making major decisions.
  • Assess Temporary Triggers: A urinary tract infection (UTI), urinary retention, recent catheterization, or a recent prostate exam can cause significant, temporary spikes in PSA [3]. Some evidence also suggests avoiding ejaculation or intense cycling for a few days before your repeat test.
  • Review Your Medications: Certain drugs for enlarged prostates or hair loss, known as 5-alpha-reductase inhibitors (like finasteride or dutasteride), artificially lower your PSA by about 50% [4]. Your doctor must know if you take these so they can accurately adjust your PSA score.
  • Check for Benign Conditions: Benign Prostatic Hyperplasia (BPH) (an enlarged prostate) or prostatitis (prostate inflammation) are very common causes of a high PSA [5]. Taking antibiotics is not recommended for a high PSA unless you have evidence of an actual bacterial infection [6]. (Seek prompt medical care for fever, chills, painful urination, or an inability to urinate).
  • Digital Rectal Examination (DRE): Your doctor will physically examine your prostate for suspicious lumps or hardening [2].

2. Refining Your Risk: Density, Calculators, and Biomarkers

If your repeat PSA remains high, the next step is to gather more context rather than guessing based on the PSA number alone.

  • PSA Density: Larger prostates naturally produce more PSA. By dividing your PSA level by the physical volume (size) of your prostate, your doctor calculates your PSA density. A low PSA density makes benign enlargement more likely, though it is a risk modifier rather than a guarantee [7][8].
  • Risk Calculators: Doctors use validated statistical tools that combine your age, ancestry, family history, PSA, and DRE findings to estimate your specific risk [9].
  • Biomarker Tests: To further clarify your risk, your doctor might order optional blood tests (like the 4Kscore or PHI) or urine tests (like SelectMDx or ExoDx) [10][11][12]. These are not definitive diagnoses, but they act as decision aids to help estimate the likelihood of clinically significant prostate cancer (cancer that is aggressive enough that it would likely require treatment).

3. Prostate MRI (mpMRI)

If your risk assessment remains concerning, many current guidelines recommend a multiparametric MRI (mpMRI) of the prostate before considering a biopsy [13]. This specialized scan looks for a suspicious lesion (abnormal area).

MRI results are graded by a radiologist using a suspicion score called PI-RADS, ranging from 1 to 5 [14]:

  • PI-RADS 1 or 2: Low suspicion. A negative MRI lowers your risk but does not completely eliminate it. Depending on your overall clinical picture, you and your doctor may decide it is reasonable to defer a biopsy and instead closely monitor your PSA [13].
  • PI-RADS 3: Equivocal (uncertain) finding. The decision to biopsy will depend heavily on your PSA density and other clinical risk factors [15].
  • PI-RADS 4 or 5: High suspicion. A biopsy is generally recommended to determine if the lesion is cancer [15].

4. The Decision to Biopsy and What to Expect

If your overall risk is high, or an MRI shows a suspicious area, a biopsy is the only way to definitively diagnose prostate cancer.

  • Targeted vs. Systematic Biopsy: If an MRI reveals a specific lesion, doctors often combine a targeted biopsy (aiming needles directly at the MRI lesion) with a systematic biopsy (sampling the rest of the prostate in a standard pattern). Research shows this combination finds significantly more clinically important cancers than either method alone, as hidden cancers can exist outside the main target [16].
  • The Procedure: Ask your doctor if they use a transrectal (through the rectum) or transperineal (through the skin behind the scrotum) approach, as they have different preparation steps and infection risks. You should also discuss pain control and how to manage any blood thinner medications you take.
  • Safety and Red Flags: After a biopsy, it is normal to see some blood in your urine or semen for a short time. However, seek urgent medical care if you develop a fever, chills, heavy bleeding, or if you are completely unable to urinate.

After the Biopsy
The tissue samples are sent to a pathology lab. If cancer is found, it will be assigned a Gleason score or Grade Group, which tells you how aggressive it is and serves as the starting point for discussing your treatment options.

Common questions in this guide

Does a high PSA result mean I have prostate cancer?
No. PSA can rise from an enlarged prostate, inflammation, infection, urinary retention, or recent procedures, and a single result cannot diagnose prostate cancer. Doctors often repeat the test and assess your other risk factors before deciding on imaging or biopsy.
What is usually the first step after an elevated PSA?
Your clinician will usually review your PSA history, medications, urinary symptoms, and possible temporary triggers, then may repeat the PSA after an appropriate interval. A prostate examination and evaluation for infection or other benign causes may also be part of the assessment.
What does a prostate MRI show after a high PSA?
A multiparametric MRI looks for areas of the prostate that may be suspicious for cancer and assigns them a PI-RADS score. PI-RADS 1 or 2 indicates lower suspicion, 3 is uncertain, and 4 or 5 is more suspicious; a lower-risk MRI does not completely rule out cancer.
When is a prostate biopsy recommended after a high PSA?
A biopsy is considered when the overall risk remains high or an MRI shows a suspicious area. It is the only way to definitively diagnose prostate cancer, and MRI-targeted samples may be combined with systematic samples.
Can benign prostate problems cause a high PSA?
Yes. Benign prostatic hyperplasia, prostatitis, urinary infection, urinary retention, recent catheterization, and a recent prostate examination can raise PSA temporarily. Antibiotics are not recommended solely for an elevated PSA unless there is evidence of a bacterial infection.
What happens if prostate cancer is found on the biopsy?
The tissue is examined by a pathology laboratory, and the cancer is assigned a Gleason score or Grade Group. This describes how aggressive it appears and helps clinicians discuss next steps and treatment options.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on prostate adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my PSA trend over time, rather than just this single latest value?
  2. 2.Do we know my prostate volume, and what is my calculated PSA density?
  3. 3.Would an optional biomarker test help clarify my risk before we decide on an MRI or biopsy?
  4. 4.If the MRI is negative (PI-RADS 1 or 2), what is my estimated residual risk, and what is our long-term follow-up plan?
  5. 5.If a biopsy is recommended, will you use a transrectal or transperineal approach, and will you combine MRI-targeted samples with systematic samples?
  6. 6.When and how will I receive the pathology results if a biopsy is performed?

References

References (16)
  1. 1

    Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-Aged Men - Data from the PROBASE Trial.

    Krilaviciute A, Becker N, Carlsson SV, et al.

    European urology 2026; doi:10.1016/j.eururo.2026.06.016.

    PMID: 42442974
  2. 2

    The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

    Vickers AJ, Eastham JA, Scardino PT, Lilja H

    Urology 2016; (91()):12-8.

    PMID: 26850815
  3. 3

    Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels.

    Kobayashi M, Kijima T, Yashi M, Kamai T

    Prostate international 2023; (11(1)):27-33 doi:10.1016/j.prnil.2022.08.001.

    PMID: 36910897
  4. 4

    Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.

    Sarkar RR, Parsons JK, Bryant AK, et al.

    JAMA internal medicine 2019; (179(6)):812-819 doi:10.1001/jamainternmed.2019.0280.

    PMID: 31058923
  5. 5

    Prostate Cancer in Primary Care.

    Merriel SWD, Funston G, Hamilton W

    Advances in therapy 2018; (35(9)):1285-1294 doi:10.1007/s12325-018-0766-1.

    PMID: 30097885
  6. 6

    Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial.

    Greiman A, Shah J, Bhavsar R, et al.

    Urology 2016; (90()):32-7.

    PMID: 26802800
  7. 7

    Predictive Value of Prostate-Specific Antigen Density on Tumour Grade in Diagnosis of Prostate Cancer: A Hospital-Based Cross-Sectional Study.

    Ozah E, Agbugui JO

    Nigerian medical journal : journal of the Nigeria Medical Association 2024; (65(6)):1124-1134 doi:10.60787/nmj.v65i6.623.

    PMID: 39877510
  8. 8

    Integrating PSA Change with PSA Density Enhances Diagnostic Accuracy and Helps Avoid Unnecessary Prostate Biopsies.

    Chou YJ, Jong BE, Tsai YC

    Diagnostics (Basel, Switzerland) 2025; (15(16)) doi:10.3390/diagnostics15162027.

    PMID: 40870878
  9. 9

    Comparison between the European Randomized Study for Screening of Prostate Cancer (ERSPC) and Prostate Biopsy Collaborative Group (PBCG) risk calculators: Prediction of clinically significant Prostate Cancer risk in a cohort of patients from Argentina.

    Orbe Villota PM, Leiva Centeno JA, Lugones J, et al.

    Actas urologicas espanolas 2024; (48(3)):210-217 doi:10.1016/j.acuroe.2023.10.002.

    PMID: 37827241
  10. 10

    Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds.

    Kawada T, Shim SR, Quhal F, et al.

    European urology oncology 2024; (7(4)):649-662 doi:10.1016/j.euo.2023.10.029.

    PMID: 37981495
  11. 11

    Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.

    Yim K, Ma C, Carlsson S, et al.

    The Journal of urology 2023; (210(4)):630-638 doi:10.1097/JU.0000000000003603.

    PMID: 37384841
  12. 12

    SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study.

    Maggi M, Del Giudice F, Falagario UG, et al.

    Cancers 2021; (13(9)) doi:10.3390/cancers13092047.

    PMID: 33922626
  13. 13

    Management of Patients With a Negative Multiparametric Prostate MRI Examination: AJR Expert Panel Narrative Review.

    Tan N, Pollock JR, Margolis DJA, et al.

    AJR. American journal of roentgenology 2024; (223(2)):e2329969 doi:10.2214/AJR.23.29969.

    PMID: 37877601
  14. 14

    Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.

    Venderink W, van Luijtelaar A, Bomers JGR, et al.

    European urology 2018; (73(3)):353-360 doi:10.1016/j.eururo.2017.02.021.

    PMID: 28258784
  15. 15

    Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.

    Pellegrino F, Stabile A, Sorce G, et al.

    European urology focus 2024; (10(4)):634-640 doi:10.1016/j.euf.2023.10.006.

    PMID: 37865591
  16. 16

    Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.

    Elkhoury FF, Felker ER, Kwan L, et al.

    JAMA surgery 2019; (154(9)):811-818 doi:10.1001/jamasurg.2019.1734.

    PMID: 31188412

This page is for informational purposes only and does not constitute medical advice. A qualified clinician should interpret your PSA and help decide whether repeat testing, MRI, biomarker testing, or biopsy is appropriate for you.